NR3C2-Related Transcriptome Profile and Clinical Outcome in Invasive Breast Carcinoma

Table 1

Clinicopathological characteristics of high and low NR3C2 expression groups.

Characteristics	Levels	Low expression of NR3C2	High expression of NR3C2	value
		533	532
Age (mean (SD))		59.02 (13.86)	57.68 (12.46)	0.097
Race (%)	Asian	43 (8.9%)	17 (3.4%)	<0.001
	Black or African American	110 (22.8%)	69 (14.0%)
	White	330 (68.3%)	407 (82.6%)
Menopause status (%)	Peri	20 (4.2%)	19 (4.0%)	0.980
	Post	346 (72.5%)	347 (72.4%)
	Pre	111 (23.3%)	113 (23.6%)
T stage (%)	T1	130 (24.5%)	145 (27.3%)	0.009
	T2	315 (59.3%)	300 (56.5%)
	T3	60 (11.3%)	77 (14.5%)
	T4	26 (4.9%)	9 (1.7%)
N stage (%)	N0	261 (49.9%)	246 (47.0%)	0.579
	N1	168 (32.1%)	181 (34.6%)
	N2	54 (10.3%)	62 (11.9%)
	N3	40 (7.6%)	34 (6.5%)
M stage (%)	M0	442 (97.4%)	447 (98.2%)	0.494
	M1	12 (2.6%)	8 (1.8%)
Pathologic stage (%)	Stage I	93 (18.0%)	87 (16.6%)	0.869
	Stage II	300 (57.9%)	306 (58.4%)
	Stage III	115 (22.2%)	123 (23.5%)
	Stage IV	10 (1.9%)	8 (1.5%)
PR status (%)	Negative	178 (35.2%)	160 (31.6%)	0.257
	Positive	328 (64.8%)	346 (68.4%)
ER status (%)	Negative	131 (25.8%)	106 (20.9%)	0.072
	Positive	376 (74.2%)	402 (79.1%)
HER2 status (%)	Negative	255 (73.9%)	293 (81.4%)	0.022
	Positive	90 (26.1%)	67 (18.6%)
PAM50 (%)	Basal	105 (19.7%)	85 (16.0%)	<0.001
	HER2	55 (10.3%)	27 (5.1%)
	LumA	228 (42.8%)	323 (60.7%)
	LumB	138 (25.9%)	64 (12.0%)
	Normal	7 (1.3%)	33 (6.2%)
Histological type (%)	Infiltrating ductal carcinoma	406 (86.0%)	351 (72.1%)	<0.001
	Infiltrating lobular carcinoma	66 (14.0%)	136 (27.9%)
Tumor status (%)	Tumor free	441 (86.3%)	469 (90.2%)	0.065
	With tumor	70 (13.7%)	51 (9.8%)
TP53 status (%)	Mut	198 (39.9%)	137 (29.8%)	0.001
	WT	298 (60.1%)	323 (70.2%)
PIK3CA status (%)	Mut	163 (32.9%)	151 (32.8%)	1.000
	WT	333 (67.1%)	309 (67.2%)